Navigation Links
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Date:8/19/2007

WESTMINSTER, Colo., Aug. 15 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the initiation of patient enrollment in a Phase 1, open-label, multi-center study of the Company's novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

"Based on our experience with PDX in patients with peripheral T-cell lymphoma, we're excited to initiate this study in patients with cutaneous T- cell lymphoma and view this effort as a natural progression of our PDX development program in hematologic malignancies," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "Therapies currently used to treat cutaneous T-cell lymphoma fail to produce durable remissions in the majority of patients with advanced disease."

In this study, patients with either relapsed or refractory cutaneous T- cell lymphoma will receive PDX as part of a weekly schedule for two or three weeks followed by one week of rest. Patients will receive starting doses of PDX at 30 mg/m2, with dose reduction in subsequent cohorts based on toxicity. Up to 56 evaluable patients will be enrolled in the study with the objective of determining the optimal dose and safety profile of PDX in this population. A total of 20 of these patients will be enrolled at what is determined to be the optimal dose and schedule. Steven Horwitz, M.D., Assistant Attending Physician, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, will serve as the study chair.

"Given the evidence of activity observed to date with PDX in patients with aggressive T-cell lymphomas, coupled with the common cell lineage between PTCL and CTCL, there is a str
'/>"/>

SOURCE Allos Therapeutics, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)... May Offer Novel Approach to Blood ...6 /- Pharmacopeia (Nasdaq:,...nt of novel small,molecule therapeutics, announced...ng Receptor Antagonist (DARA), showed statisticall... 2a study in patients with mild to,moderate hypert...
(Date:5/15/2008)...wswire/ -- Eisai Corporation of North,America anno...tracts about,compounds in the company,s oncology p...y research have been accepted for presentation at ... Clinical Oncology (ASCO),taking place in Chicago...abstracts on Eisai marketed products and,investiga...
(Date:5/15/2008)...light safety profile of BSI-201 in ... Calif., May 15 /- BiPar Sciences, In...eloping novel cancer therapies,today announced th...1, will,be presented at the 2008 American Society ...Findings will be presented from the first in human...
(Date:5/15/2008)...wswire-FirstCall/ -- Cytopia Limited,(ASX: CYT) to...ral,presentation on CYT997 at the 2008 Annual Meet...ASCO) will be accessible to the public via ASCO,s,...ay 15 May (US EDT)., The oral presentation, entit...ic and vascular disrupting agent, in patients with...
Breaking Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2No strong evidence linking amateur boxing with long term brain injury 3021 1No strong evidence linking amateur boxing with long term brain injury 3021 2Caraco Pharmaceutical Laboratories Ltd Announces Tentative FDA Approval for Generic Zyrtec Chewable 28R 29 3018 1Caraco Pharmaceutical Laboratories Ltd Announces Tentative FDA Approval for Generic Zyrtec Chewable 28R 29 3018 2Story ideas from Molecular 26amp 3B Cellular Proteomics 701 1Story ideas from Molecular 26amp 3B Cellular Proteomics 701 2Story ideas from Molecular 26amp 3B Cellular Proteomics 701 3Story ideas from Molecular 26amp 3B Cellular Proteomics 701 4Study Rates Heart Health of Popular Diet Plans 3010 1Study Rates Heart Health of Popular Diet Plans 3010 2Study Rates Heart Health of Popular Diet Plans 3010 3Study Rates Heart Health of Popular Diet Plans 3010 4
...ciences, Ace393, the World,s First Commercial Vacc...ter Successfully,Completes Phase I Clinical Trials...immunogenicity , ODENSE, Denmark, March 28, 2007 -...ny is pleased to announce the successful,completio...,ACE393, the world,s first commercial vaccine for...
...ilot Study Demonstrates 50% Survival in Valortim-T...d., March 29, 2007,/PRNewswire-FirstCall/ -- Medar...and PharmAthene, Inc., a privately held,biotechnol...ense,countermeasures, today announced that Valorti...andidate being developed for the,prevention and tr...
Other Medicine Technology:Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 2Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 3Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8
(Date:5/16/2008)... Month-long Campaign to Emphasize the Importance... 16 /PRNewswire/ -- National dental insurer United...nth, a collaboration,between Oral Health America a... the importance of oral health to overall health. ...n the United States for the first time,making it ...
(Date:5/16/2008)... , (Washington) Declaring that Primary care medi...D, FACP, president of the American College of Phys...atives of employers and consumers to issue a call ...retain general internists and other primary care p...tate of primary care medicine in the U.S., Dr. Dal...
(Date:5/16/2008)... Live Web Cast Scheduled for May 19 at 10:...re-FirstCall/ - Response Biomedical,Corporation (T...ne Kay,Chief Executive Officer, is scheduled to p...ealthcare Conference on Monday May 19th at 10:15 a...l be available on the Company,s,Web site at, http:...
(Date:5/16/2008)... HARRISBURG, Pa., May 16 /PRNewswire-USNewswi...4, is an opportunity to highlight the dedication,o...re citizens to become,trained EMS volunteers, acco...son., This year,s theme, "EMS: Your Life is Our M...ncy is or when it occurs, EMS is there to provide,...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:PA Secretary of Health Announces 'Emergency Medical Services Week,' May 18 - 24 2
...ancer known as cutaneous T-cell lymphoma became su...en 1973 and 2002 , according to a report in the Ju...the disease vary by race, sex and geographic area.... certain cells of the lymph system (called T lymph...
...nts undergoing tonsillectomy, or removal of the to...ir sense of taste following the procedure . Toget...the mouth, the sense of taste contributes consider... and drinking and thus plays a major role in the e...
...ding to new research from The University of Arizon... swept across Africa more recently than previously...nkeys shows that an HIV-like virus, simian immunod... those monkeys after the lineage split into four s...
...ability to listen to a phone message in one ear wh...prehend what both are sayingis an important commu...nes, say researchers of the National Institute on ...ers (NIDCD), one of the National Institutes of Hea...
Other Medicine News:Health News:Cutaneous T-cell Lymphoma Shows Steady Increase 2Health News:Patients Undergoing Tonsillectomy Shows No Change of Taste 2Health News:Evolution of HIV from African Greek Monkeys 2Health News:Evolution of HIV from African Greek Monkeys 3Health News:Genes Influence the Ability to Listen Two Things at a Time 2Health News:Genes Influence the Ability to Listen Two Things at a Time 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Medicine Products: